Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone

被引:22
|
作者
Walther, Sebastian [1 ]
Horn, Helge [1 ]
Razavi, Nadja [1 ]
Koschorke, Philipp [1 ]
Wopfner, Alexander [1 ]
Mueller, Thomas J. [1 ]
Strik, Werner [1 ]
机构
[1] Univ Bern, Univ Hosp Psychiat, CH-3000 Bern 60, Switzerland
关键词
actigraphy; treatment effects; quantitative motor activity; ATYPICAL ANTIPSYCHOTICS; HALOPERIDOL; PSYCHOMOTOR; SYMPTOMS; SCALE; QUETIAPINE; MOVEMENTS; EFFICACY; SIGNS;
D O I
10.1097/JCP.0b013e3181d2ef6f
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are indications that atypical antipsychotics differ in the probability of causing motor retardation. Whereas olanzapine seems to exert sedation, risperidone might slow patients because of parkinsonism or increased negative symptoms. Objective data on gross motor activity are not available. We present actigraphic data of 16 schizophrenia patients treated with olanzapine (mean dose, 21.1 mg/d) and 23 with risperidone (mean dose, 4.7 mg/d) to investigate possible differences in their effects on motor activity. Participants wore actigraphs continuously for 24 hours at the nondominant arm. Groups did not differ in age, Positive and Negative Syndrome Scale scores, duration of illness, and number of episodes. Patients treated with olanzapine had higher activity levels than those treated with risperidone (P = 0.024); this effect was robust and also present after covarying for chlorpromazine equivalents and Positive and Negative Syndrome Scale scores. Movement index (proportion of active episodes) and the average duration of immobility, however, failed to show any difference between groups. The results indicate that patients on olanzapine are more active during the day than patients on risperidone. It remains unclear whether this difference is due to subthreshold parkinsonism with risperidone or stronger beneficial effects of olanzapine on psychomotor slowing. Because the average duration of immobility remained unaffected, sedation is not likely to be the cause for the observed differences.
引用
收藏
页码:181 / 184
页数:4
相关论文
共 50 条
  • [21] Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine
    Mulsant, BH
    Gharabawi, GM
    Bossie, CA
    Mao, L
    Martinez, RA
    Tune, LE
    Greenspan, AJ
    Bastean, JN
    Pollock, BG
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (12) : 1708 - 1714
  • [22] Prolactin levels in schizophrenia patients treated with paliperidone switching from risperidone, aripiprazole and olanzapine
    Young, C. Ah
    Young, K. Eun
    Young, L. Nam
    Min, A. Yong
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S529 - S530
  • [23] Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
    Basson, BR
    Kinon, BJ
    Taylor, CC
    Szymanski, KA
    Gilmore, JA
    Tollefson, GD
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (04) : 231 - 238
  • [24] Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Volavka, J
    Czobor, P
    Nolan, K
    Sheitman, B
    Lindenmayer, JP
    Citrome, L
    McEvoy, JP
    Cooper, TB
    Lieberman, JA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (02) : 225 - 228
  • [25] Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
    Tran, PV
    Tollefson, GD
    Andersen, SW
    Kuntz, AJ
    Hamilton, SH
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 205 - 205
  • [26] Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders
    Thomas, A
    Grainger, D
    Andersen, S
    Tollefson, G
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 147 - 147
  • [27] A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia
    Zhao, Z
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 173 - 173
  • [28] Cost analysis of olanzapine versus risperidone in the treatment of uncontrolled schizophrenia
    Zhao, Z
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 172 - 173
  • [29] Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Volavka, J
    Czobor, P
    Cooper, TB
    Sheitman, B
    Lindenmayer, JP
    Citrome, L
    McEvoy, JP
    Lieberman, JA
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (01) : 57 - 61
  • [30] Reducing violence risk in persons with schizophrenia: Olanzapine versus risperidone
    Swanson, JW
    Swartz, MS
    Elbogen, EB
    Van Dorn, RA
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (12) : 1666 - 1673